A case of pericardial angiosarcoma with refractory pericardial tamponade treated with multidisciplinary therapy with pericardial fenestration, radiotherapy and chemotherapy

Hirano Satoshi, Yamanaka Kyoko, Ichinose Shuji, Ikeda Atsushi, Hayama Noriko, Shimizu Shinichiro, Aruga Takashi, Uchida Osamu, Nakamura Sukeyuki

ABSTRACT

Introduction: Outcomes for patients with pericardial angiosarcoma, especially with metastatic disease are very poor, even when these patients are treated with chemotherapy or radiotherapy. Case Report: This report describes a case of a 50-year-old male with pericardial angiosarcoma presenting with cardiac tamponade. Repeat pericardiocentesis showed bloody fluid with cytopathology negative for malignant cells. Pericardial fenestration was performed to prevent recurrent pericardial tamponade due to poor drainage. A diagnosis of cardiac angiosarcoma was made based on the resected pericardium and a biopsied specimen from gluteus medius muscle. The patient responded to combination therapy with docetaxel and radiotherapy. However, the patient died four months after diagnosis due to intraperitoneal bleeding from liver metastases. The patient was not dependent on a chest tube or a pericardial drain before he died. At autopsy, only a small amount of residual tumor was revealed around the heart. Conclusion: There is a possibility that palliative local control against refractory cardiac tamponade could be obtained via multidisciplinary therapy with pericardial fenestration, radiotherapy, and chemotherapy.
A case of pericardial angiosarcoma with refractory pericardial tamponade treated with multidisciplinary therapy with pericardial fenestration, radiotherapy and chemotherapy

Hirano Satoshi, Yamanaka Kyoko, Ichinose Shuji, Ikeda Atsushi, Hayama Noriko, Shimizu Shinichiro, Aruga Takashi, Uchida Osamu, Nakamura Sukeyuki

ABSTRACT

Introduction: Outcomes for patients with pericardial angiosarcoma, especially with metastatic disease are very poor, even when these patients are treated with chemotherapy or radiotherapy. Case Report: This report describes a case of a 50-year-old male with pericardial angiosarcoma presenting with cardiac tamponade. Repeat pericardiocentesis showed bloody fluid with cytopathology negative for malignant cells. Pericardial fenestration was performed to prevent recurrent pericardial tamponade due to poor drainage. A diagnosis of cardiac angiosarcoma was made based on the resected pericardium and a biopsied specimen from gluteus medius muscle. The patient responded to combination therapy with docetaxel and radiotherapy. However, the patient died four months after diagnosis due to intraperitoneal bleeding from liver metastases. The patient was not dependent on a chest tube or a pericardial drain before he died. At autopsy, only a small amount of residual tumor was revealed around the heart. Conclusion: There is a possibility that palliative local control against refractory cardiac tamponade could be obtained via multidisciplinary therapy with pericardial fenestration, radiotherapy, and chemotherapy.

Keywords: Cardiac tamponade, Multidisciplinary therapy, Pericardial angiosarcoma, Pericardial fenestration, Radiotherapy

How to cite this article

INTRODUCTION

Pericardial angiosarcoma is extremely rare, but this entity should still be included in the differential diagnosis of bloody pericardial effusion, even when cytopathology is negative for malignant cells. Outcomes for patients with metastatic disease are very poor, even when these patients are treated with chemotherapy or radiotherapy. This report describes a case of a patient with pericardial angiosarcoma presenting with recurrent pericardial tamponade and illustrates that palliative local control against cardiac tamponade can be obtained via multidisciplinary therapy with pericardial fenestration, radiotherapy, and chemotherapy.

CASE REPORT

A 50-year-old male with a history of gout treated with febuxostat was referred for the evaluation for a three-day history of dyspnea and pericardial effusion. He admitted to heavy alcohol consumption and 28 pack-years of former smoking. On physical examination, his pulse was 108 bpm, blood pressure was 128/88 mmHg, and oxygen saturation was 98% on room air. His body temperature was 37.4°C. Heart murmurs and lung rales were not heard. The rest of the physical examination was unremarkable. His basic laboratory findings were unremarkable except for elevation of hepatocellular enzymes (aspartate aminotransferase of 42 IU/L and alanine aminotransferase of 50 IU/L) and C-reactive protein (3.03 mg/dL). Electrocardiogram showed sinus rhythm and low voltage tracings. Chest X-ray showed cardiac enlargement (Figure 1A). Echocardiography demonstrated massive pericardial effusion (Figure 1B).

Pericardiocentesis was performed, and 1600 mL of bloody fluid was aspirated. Repeat fluid cytologic examination revealed no malignant cells. The results of examinations for tuberculosis and other bacterial agents were negative. A pericardial drain was placed, and drain output was 600 to 800 mL of bloody fluid every other day. Contrast-enhanced computed tomography (CT) scan of the chest showed large pericardial effusion and swelling of mediastinal lymph nodes (Figure 1C). There was no evidence of intracardiac abnormality. 18F-labeled deoxyglucose (FDG) positron emission tomography scan showed increased FDG uptake in mediastinum nodules, pericardium, gluteus medius muscle, and cervical vertebrae (Figure 1D). About two weeks later, the pericardial drain was removed to prevent infection. However, two weeks after removal of pericardial drain, the patient developed syncope with massive pericardial effusion. A pericardial drain was placed but was not effective due to the high viscosity of the pericardial fluid. Therefore, pericardial fenestration was performed to prevent recurrent cardiac tamponade.

From the resected pericardium and the specimen from a gluteus medius muscle biopsy, a diagnosis of pericardial angiosarcoma was made. Proliferation of atypical short spindle or oval or epithelioid cells with hyperchromatic irregular nuclei and eosinophilic cytoplasm arranged in papillary structures or situated around variably gaping organization was demonstrated. Immunohistochemically, many atypical cells were positive for CD31, CD34, and Fli-1 (Figure 2). Desmin, S-100, D2-40, cytokeratins (CAM5.2, AE1/AE3), EMA, calretinin, and STAT6 were negative.

The patient was treated with concomitant chemoradiotherapy using a total dose of 40 Gy (2 Gy/fraction) for 4 weeks and docetaxel at a dose of 25 mg/m² weekly after administration of 300 mg of carboplatin into the pericardial space. The pericardial drain was removed after administration of carboplatin, and the chest drainage tube was also removed two weeks later.

After 1 month, multiple brain, pulmonary, and liver metastases were demonstrated. Therefore, treatment with docetaxel was stopped, and pazopanib was initiated. Two months later, he presented to our hospital with palpitations, dyspnea on exertion, and new-onset dizziness. Laboratory work was performed and showed severe anemia with a hemoglobin of 5.6 g/dL. He received 2 units of red blood cells, but his condition did not improve. Two days later, he was readmitted to our hospital for further evaluation. His heart rate was 101 bpm, blood pressure was 93/65 mmHg, and oxygen saturation

---

Figure 1: (A) Chest radiograph, at the time of admission, showing cardiac enlargement, (B) Two-dimensional echocardiogram showing large pericardial effusion with tamponade physiology, (C) Axial computed tomography section through the chest after intravenous contrast, mediastinal window showing a massive pericardial effusion without any evidence of intracardiac abnormality, and (D) 18F-labeled deoxyglucose (FDG) positron emission tomography scan, showing increased FDG uptake in mediastinum nodules, pericardium, gluteus medius muscle, and cervical vertebrae.
was 96% on room air. On initial laboratory evaluation, his hemoglobin level was 5.6 g/dL. He also complained of right upper abdominal pain. Contrast-enhanced CT scan of the abdomen showed intraperitoneal hemorrhage due to multiple liver metastases (Figure 3A).

Unfortunately, the patient died four days after readmission due to intraperitoneal bleeding.

At autopsy, fatal massive intraperitoneal hemorrhage arising from liver metastases was demonstrated (Figure 3B). Although multiple nodular tumors remained within the pericardium, only a small pericardial effusion was demonstrated (Figure 4). Microscopically, most of the pericardial tumors were necrotic. Multiple lung metastases were also demonstrated, but pleural effusion was mild (about 300 mL in each thoracic cavity).

**DISCUSSION**

Primary cardiac angiosarcoma is extremely rare but is the most common primary cardiac malignancy. Therefore, cardiac angiosarcoma should be included in the differential diagnosis of cardiac tamponade. Unfortunately, this tumor is not easy to diagnosis due to its minimal incidence and difficult location to approach. Pericardiocentesis and tissue biopsy are often used for diagnosis. However, pericardial fluid cytology analysis is unreliable and should not be used, because malignant cells are very rarely found in the bloody fluid, even when the tumor has invaded into the pericardium, as in the present case. For accurate diagnosis, surgical exploration and intraoperative frozen sections are needed [1].

Outcomes associated with these tumors are very poor due to their aggressive character and due to late diagnosis, with 80% of patients already presenting with metastases at the time of diagnosis [2]. Surgical resection of primary tumor should be attempted when feasible, as...
overall survival (OS) may be improved. Few studies have characterized survival outcomes in patients with cardiac angiosarcoma and metastatic disease. Hong et al. analyzed 10 patients who presented with metastatic disease and reported a median OS of only six months [3].

The optimal chemotherapy regimen for these aggressive tumors has not been established. Recently, Okiyama et al. reported that low-dose docetaxel therapy was effective for treatment of angiosarcoma of the skin [4]. On the other hand, Nakamura-Horigome et al. reported that docetaxel and radiotherapy was an effective treatment for cardiac angiosarcoma [5]. Their patient was treated with standard fractionated radiotherapy with a total dose of 42 Gy (2 Gy/fraction) for 4 weeks. The patient received docetaxel, 25 mg/m² weekly. With this treatment, the radiation dosage was reduced, using docetaxel as a radiosensitizer to decrease the adverse effects of high-dose standard fractionated radiotherapy. Subsequent cycles docetaxel were administered as maintenance therapy (2 weeks of treatment, 1 week of rest) until disease progression. Suderman et al. described a case of cardiac angiosarcoma treated with the same method. Their patient survived for more than 16 months [6].

Pazopanib is a synthetic imidazolyl pyrimidine that functions as a multi-targeted tyrosine kinase inhibitor with a high affinity for vascular endothelial growth factor receptors. The median length of progression-free survival and overall survival of patients with angiosarcoma treated with pazopanib after one or more cytotoxic regimens was reported as 3.2 months and 8.0 months, respectively [7]. A recent case report noted a durable response of more than 10 months when using pazopanib for treatment of pericardial angiosarcoma [8].

In our patient, multiple metastases were demonstrated at the time of diagnosis, and recurrent pericardial effusion was hard to resolve. Therefore, multidisciplinary therapy with pericardial fenestration, radiotherapy, and chemotherapy with docetaxel followed by pazopanib was performed. The treatment was effective for local tumor control and for maintenance of quality of life. The patient was not dependent on a chest tube or a pericardial drain until the time of his death.

CONCLUSION

We conclude that multidisciplinary approaches involving palliative surgery, radiotherapy, and chemotherapy may offer better quality of life in cases of cardiac angiosarcoma even in patients with metastatic disease.

*********

Acknowledgements

We thank Dr. Hisaoka Masanori for his diagnostic expertise.

Author Contributions

Satoshi Hirano – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Kyoko Yamanaka – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Shuji Ichinose – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2015 Satoshi Hirano et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES


Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.